Application of isatis root and isatis root particle in medicament for preventing and controlling endotoxin endotoxemia

Abstract

The invention discloses an application of radix isatidis in preparing medicine curing endotoxemia and an application of radix isatidis particle in preparing medicine curing endotoxemia. The invention is characterized in that: the radix isatidis can directly neutralize and degrade the endotoxin, and can reduce the amount of the endotoxin, and can evidently antagonize DIC biological effect caused by the endotoxin and reduce the thrombosis rate of vital organ organization; simultaneously, the radix isatidis particle can prevent the endotoxin stimulating expression of extension spike protein mRNA for vital organ membrane structure of mouse, and can reduce the activity increasing degree of p38 mitogen activited protein kinase induced by the endotoxin.

Description

Technical field [0001] The invention relates to a new medicinal use of Isatis indigotica, in particular to its application in preparing drugs for preventing and treating endotoxemia. Background technique [0002] Bacterial endotoxin (endotoxin) is a lipopolysaccharide (LPS) component of the cell wall released when gram-negative bacteria grow or lyse when it dies. After entering the body, it interacts with host cells and exhibits a wide range of biological activities. It mediates immunity. And the key pathogenic factor of inflammatory response. Endotoxemia is caused by excessive endogenous and exogenous endotoxins entering the blood circulation, stimulating the body's immune cells to release a variety of cytokines, destroying the body's inflammatory response balance, leading to microcirculation disorders and tissue damage, and further causing septic shock, High-risk diseases such as multiple organ failure. [0003] At present, studies have found that endotoxemia is not only presen...

AI Technical Summary

Problems solved by technology

In terms of western medicine, polymyxin B has too much nephrotoxicity; lactulose, Livzon Changle and bifidotriple live bacterial preparations are only suitable for reducing intestinal ET absorption; the monoclonal antibody Centoxin approved by the FDA in the United States is effective in reducing late-stage ET absorption. It is very effective in terms of mortality in patients with septic shock, but the treatment is extremely expensive; anti-endotoxin proteins such as polymyxin B nonapeptide, which is still in the research stage, have good prospects for the treatment of endotoxic diseases, but due to the The specificity is too strong, the cross-protection effect is poor or the affinity for endotoxin is not strong, and the resistance and immunity of the body are weakened. Its long-term effectiveness and safety need to be further observed and evaluated, and it has not been widely used clinically. In addition, the investment is too high, and the target has now been turned to the development and research of traditional Chinese medicine and natural medicine, especially traditional Chinese medicine for clearing away heat and detoxification.